SYNTHESIS: Cancer research meets evolutionary biology
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
There is increasing evidence that Darwin’s theory of evolution by natural selection provides insights into the etiology and treatment of cancer. On a microscopic scale, neoplastic cells meet the conditions for evolution by Darwinian selection: cell reproduction with heritable variability that affects cell survival and replication. This suggests that, like other areas of biological and biomedical research, Darwinian theory can provide a general framework for understanding many aspects of cancer, including problems of great clinical importance. With the availability of raw molecular data increasing rapidly, this theory may provide guidance in translating data into understanding and progress. Several conceptual and analytical tools from evolutionary biology can be applied to cancer biology. Two clinical problems may benefit most from the application of Darwinian theory: neoplastic progression and acquired therapeutic resistance. The Darwinian theory of cancer has especially profound implications for drug development, both in terms of explaining past difficulties, and pointing the way toward new approaches. Because cancer involves complex evolutionary processes, research should incorporate both tractable (simplified) experimental systems, and also longitudinal observational studies of the evolutionary dynamics of cancer in laboratory animals and in human patients. Cancer biology will require new tools to control the evolution of neoplastic cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phylogenies and the Comparative Method
Felsenstein, J. (1985) · The American Naturalist · doi:10.1086/284325 · Cited by 9,793
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 5×
“In solid tumors, clinicians are understandably reluctant to initiate further invasive procedures to biopsy a neoplasm after the extended trauma of cancer therapy has failed.”
BackgroundInfluentialClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683 · cited 2×
“…stem or nonstem cell component is responsible for neoplasm self-renewal, there is broad agreement that therapeutic targeting of the self-renewing cells is crucial for effective disease management (Wang 2007). ª 2009 The Authors 66 Journal compilation ª 2009 Blackwell Publishing Ltd 2 (2009) 62–70”
BackgroundIn vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484 · cited 3×
“Anti-androgen therapies in prostate cancer select for mutations that cause hypersensitivity in the androgen receptor (AR) (Taplin et al. 1999) as well as amplification of that gene (Visakorpi et al. 1995).”
Background
Cited by
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Self-citationNatural Products as Anticancer Agents: Current Status and Future Perspectives
Naeem, A., Hu, P., Yang, M., Zhang, J., Liu, Y., Zhu, W., & Zheng, Q. (2022) · Molecules · doi:10.3390/molecules27238367 · Cited by 607
Tumorigenesis: it takes a village
Tabassum, D. P., & Polyak, K. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3971 · Cited by 564
Tree inference for single-cell data
Jahn, K., Kuipers, J., & Beerenwinkel, N. (2016) · Genome Biology · doi:10.1186/s13059-016-0936-x · Cited by 302
Human influences on evolution, and the ecological and societal consequences
Hendry, A. P., Gotanda, K. M., & Svensson, E. I. (2017) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2016.0028 · Cited by 298
Metadata
- Authors
- Pepper, J. W., Scott Findlay, C., Kassen, R., Spencer, S. L., & Maley, C. C.
- Venue
- Evolutionary Applications
- Publisher
- Wiley
- Published
- 2009-01-27
- Volume
- 2
- Issue
- 1
- Pages
- 62-70
- ISSN
- 1752-4563 (ISSN-L)
- 1752-4571
- OpenAlex
- W2149552304
- Cited by
- 109
- References
- 8
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SYNTHESIS: Cancer research meets evolutionary biology. https://app.cochat.ai/papers/10.1111/j.1752-4571.2008.00063.x
- The paper
- Pepper, J. W., Scott Findlay, C., Kassen, R., Spencer, S. L., & Maley, C. C. (2009). SYNTHESIS: Cancer research meets evolutionary biology. Evolutionary Applications. https://doi.org/10.1111/j.1752-4571.2008.00063.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.